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For the past 60 years, the central nervous system has been considered immunologically privileged. Yet
results from diverse fields show clear and convincing evidence of bidirectional communication between
the nervous and immune systems.The observations that immune responses
are blunted in the central nervous system
(CNS) and that the blood-brain barrier
(BBB) prevents infiltration of immune cells
and molecules into the CNS originally
established the belief that the nervous
and immune systems were isolated with
little interaction except during disease
and/or trauma. This dogma was generally
accepted for many years, and immune
responses within the CNS were studied
almost exclusively in response to injury
and in a handful of ‘‘immune-mediated’’
diseases. Recently, however, a true para-
digm shift in our understanding of neural-
immune interactions has occurred due to
the convergence of unexpected results
from diverse fields showing clear and
convincing evidence of bidirectional
communication between these systems.
Although pioneers in this field still meet
resistance fromboth the traditional neuro-
science and immunology communities,
interest in this new frontier in neuroscience
is accelerating at a dizzying pace and has
becomea source of great expectations for
future discoveries that will allow us to
better understand and treat conditions
that have thus far eluded explanation.
The classical view that immune
responses occur in the CNS exclusively
following brain injury received support
for decades. Until recently, the BBB was
thought to be an impermeable barrier to
immune cells and most diffusible factors
produced in the periphery. In response
to insult, glial cells in the brain produce
diffusible factors called cytokines, a large
and diverse family of proteins that cross
the compromised BBB and signal recruit-
ment and activation of immune cells (see
Deverman and Patterson, 2009 [this issue
of Neuron]). In response, blood-derivedmonocytes migrate through the compro-
mised BBB into the CNS and aidmicroglia
in causing neural inflammation, degenera-
tion, and cell death. The detrimental
effects of immune cell infiltration into the
CNS have been well documented, espe-
cially in the context of autoimmune
disorders (see Bhat and Steinman, 2009
[this issue of Neuron]) and are the focus
of drug development to prevent this
infiltration.
The dogma of CNS immune-privilege
began to break down with the realization
that immune cell infiltration into the
CNS may be more common than previ-
ously believed. Indeed,many neurological
diseases, including Alzheimer’s and Par-
kinson’s disease, are accompanied by
neuroinflammation, andanti-inflammatory
drugs can dramatically reduce the risk
for Alzheimer’s and Parkinson’s diseases
(see Lucin and Wyss-Coray, 2009 [this
issue of Neuron]). Despite these exciting
findings, the role of the immune system
in neurodegenerative disease remains
unclear. Is this neuroinflammation the
result of increased immune cell infiltration
into theCNS, increased levels of cytokines
within the brain, or microglial activation
caused either by peripheral stimuli or by
local immune responses to protein aggre-
gates that form early in the progression of
many of these diseases? Once the cause
of the increased neural inflammation is
identified, it should be possible to design
drug therapies that specifically target the
altered immune response at distinct
stages of these diseases.
In addition to brain injury and neurolog-
ical disease, there is now growing
evidence that neural-immune crosstalk
may even occur in nondisease conditions,
including in the healthy brain. BBB perme-Neuronability can change as a result of many
factors, including subclinical infection,
exposure to environmental toxins, addic-
tive drugs, extreme stress, and possibly
some medications. Some bacteria and
viruses have even become adept at
breaching this barrier (see van den Pol,
2009 [this issue of Neuron]). Finally, it
has recently been suggested that the
BBB becomes more permeable with
healthy aging. Consistent with this obser-
vation, healthy aging is accompanied by
increased immune activation, expression
of genes related to cellular stress and
inflammation, and immune cell infiltration
into the CNS (see Lucin and Wyss-Coray,
2009). Finally, microglia may become
senescent with age, leading to inefficient
clearance of toxic protein aggregates in
neurodegenerative diseases.
Remarkably, it is not just immune cells
that participate in neural-immune cross-
talk; larger immune proteins, such as
antibodies, also appear to infiltrate the
brain at times of increased BBB perme-
ability. Such infiltration has been well
documented in autoimmune diseases.
For example, autoantibodies produced
in systemic lupus erythematosus cross
the BBB and may contribute to the cogni-
tive impairments in this disease (see
Bhat and Steinman, 2009). In human
development, maternal antibodies (IgG)
are passed to the fetus during gestation
to provide passive immunity where they
serve a protective role until the child’s
immune system matures. A growing
body of evidence suggests that some
mothers of children with autism produce
detrimental antibodies that target brain
proteins in their infants (reviewed in En-
strom et al., 2009). While the role of these
antibodies in autism is currently unknown,64, October 15, 2009 ª2009 Elsevier Inc. 9
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consequences of prenatal exposure to
antibodies from mothers of children with
autism show significant increases in
behavioral changes in the offspring that
mimic autism endophenotypes (Enstrom
et al., 2009).
Increased BBB permeability during
gestation suggests that elevated and/or
abnormal peripheral immune responses
could have profound effects on the
developing brain. In fact, several groups
have reported a potential link between
infections during pregnancy and neuro-
developmental disease in the offspring.
The development of a mouse model of
maternal infection has added strong
support for a link between maternal
immune activation, elevated cytokines,
and changes in brain development (see
Deverman and Patterson, 2009). More-
over, specific haplotypes of MHCI mole-
cules correlate with increased incidence
of schizophrenia and autism, and a
growing number of genes encoding
immune proteins have been reported to
be dysregulated in autistic and schizo-
phrenic brains (see Boulanger, 2009 [this
issue of Neuron]). Ultimately, large-scale
epidemiological studies are required to
elucidate the true contribution of maternal
infection to these disorders (see Ellman
and Susser, 2009 [this issue of Neuron]).
Determining if, andhow, immunedysregu-
lation contributes to the development of
any of these neurodevelopmental disor-
ders is of paramount importance because
that informationwill guide future therapies.
A prevailing hypothesis in this field is
that neural-immune crosstalk is often
detrimental, mediated by cytokines that
cross the BBB and signal a peripheral
immune response in the CNS. However,
cytokines are also normally produced in
the healthy brain where they play critical
roles in stem cell renewal, cell fate
decisions, neuronal differentiation, and
synaptic plasticity required for learning
and memory (see Deverman and Patter-
son, 2009; Carpentier and Palmer, 2009
[this issue of Neuron]; Boulanger, 2009).
Because cytokines are involved in both
normal neuronal function and inmediating
the effects of neural inflammation and
disease, they appear to be critical effec-
tors that could translate the immune
status of an individual into changes in
cognition. Cytokines generally fall into10 Neuron 64, October 15, 2009 ª2009 Elsetwo categories: proinflammatory cyto-
kines cause destruction of neural
pathways, whereas anti-inflammatory
cytokines are neuroprotective. However,
recent evidence suggests that cytokines
can exert both neuroprotective and
destructive roles, depending on the
context and timing. Thus, it is the balance
between the protective and destructive
roles of cytokines altered in the brain that
determines their effects on neural function
and has profound implications for drug
therapies that target specific cytokines.
The final proverbial nail in the coffin of
CNS immune-privilege came about ten
years ago with the observation that
classes of ‘‘classic’’ immune molecules,
such as major histocompatibility complex
(MHCI) molecules, putative MHCI recep-
tors, and components of the complement
cascade play important roles in many
aspects of neural development and func-
tion (see Boulanger, 2009; Shatz, 2009
[this issue of Neuron]). These immune
molecules are clearly present on neurons
and glia in the brain, and emerging
evidence suggests that MHCI molecules,
their putative receptors, and members of
the complement cascade play important
roles in neural plasticity as well as in infor-
mation processing in the olfactory system
(Restrepo et al., 2006). Despite growing
evidence supporting roles for immune
molecules in many aspects of neural
development, these observations have
been so antithetical to the dogma of
CNS immune-privilege that this rapidly
growing and exciting new field of research
still meets resistance from the basic
neurobiology community.
In contrast, many immunologists seem
to have embraced the idea that there
are functional similarities between the
immune and nervous systems. About ten
years ago, it was proposed that special-
ized contacts between immune cells
might be similar to synaptic contacts
between neurons; these contacts were
called immune synapses. Synapses in
either system are defined as stable adhe-
sions between two distinct cells that allow
for information transfer through directed
secretion. Neuronal synapses are asym-
metric structures that use neurotransmit-
ters to transmit information from the
presynaptic axon terminal to receptors
on the postsynaptic cell. The immunolog-
ical synapse (IS) is an asymmetric contactvier Inc.between two cells (e.g., a T cell and
an antigen-presenting cell [APC]) that
allows controlled secretion of molecules
between the engaged cells to effect
immune activation. Interestingly, for both
neuronal and immune synapses, many of
the same cell adhesion molecules regu-
late the specificity of synapse formation
and interact with networks of cytoplasmic
scaffolding and signaling proteins to
regulate synapse function (reviewed in
Yamada and Nelson, 2007).
Recent advances in understanding
a less well-known kind of immunological
synapse—the natural killer (NK) cell
immunological synapse (NKIS)—may
have especially interesting implications
for our understanding of the plasticity of
neuronal synapses. NK cells determine
the health of other cells by recognizing
the balance of activating and inhibitory
ligands expressed by each target. NK
cells form transient adhesions to nearby
cells and detect the presence, or absence
of MHCI molecules on them. A lack of
MHCI on the target, caused by viral
infection or tumorigenesis, favors forma-
tion of an activating IS using mechanisms
similar to those described for T cell-APC
synapses. Conversely, the presence of
MHCI on the target results in binding
of MHCI to NK inhibitory receptors,
including PirB and Ly49 receptors, which
initiates dominant inhibitory signaling
and prevents the formation of the NK
cell activation synapse (reviewed in
Krzewski and Strominger, 2008). Because
both PirB and Ly49 NK inhibitory recep-
tors are present in the CNS, it is possible
that these receptors mediate the effects
of MHCI on synaptic refinement (see
Boulanger, 2009; Shatz, 2009).
Although there has been much recent
focus on immune molecules present at
neural synapses, there is equally exciting
data showing that proteins traditionally
studied at neural synapses play important
roles in immune function (reviewed in
Habibi et al. 2009). Perhaps the most
compelling example in this literature is
the role for glutamate receptors on
several types of immune cells. Glutamate
receptors are expressed on peripheral
blood mononuclear cells (PBMC) and
T cells, where they are believed to be
involved in immune development, activa-
tion, response, and survival. In addition,
GABA receptors on PBMCs also appear
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et al., 2009). Thus, it is possible that a
genetic defect in a common receptor
pathway, such as either of these recep-
tors, may manifest in changes in both
neuronal and immune function.
Taken together, these data indicate that
‘‘immune proteins’’ play integral roles in
neural development, function, and plas-
ticity, and ‘‘neural proteins’’ play equally
important and interesting roles in the
immune system. Do these molecules
play similar or distinct roles in the two
systems? If they play similar roles, and if
there is truly open dialogue between the
two systems, then peripheral immune
responses might affect shared proteins
in the nervous system, altering neural
development and/or function either tran-
siently or pathologically during sys-
temic infection or disease. Interestingly,
illnesses accompanied by high levels of
systemic proinflammatory cytokines are
often associated with cognitive problems,
perhaps due to disruption of normal
cytokine functioning in synaptic plasticity
(seeBoulanger, 2009).Moreover, amouse
model that lacks a functional immune
system (severe combined immunodefi-
cient; SCID mice) shows impairment in
the acquisition of cognitive tasks, and
acute depletion of adaptive immunity in
normal adult mice impairs their learning
behavior (Brynskikh et al., 2008). Finally,
our immune responses might be altered
not just in disease but even by major
events in our lives. Increased levels of
proinflammatory cytokines and neural
inflammation, stimulated by chronic
stress (see Sorrells et al., 2009 [this issue
of Neuron]), likely also contribute to the
altered synaptic plasticity and long-term
cognitive changes in depression. Thus, in
addition to investigating whether neural-
immune crosstalk could and should be
targeted in therapies for neurodevelop-
mental and neurodegenerative diseases,
perhaps even subtle psychiatric changes
could be improved with directed manipu-
lation of immune signalingwithin the brain.
These new discoveries could be taken
as evidence that immune responses
within the CNS are always deleterious.
But such extreme interpretations of this
field are overly simplistic and potentially
more harmful to human health than the
altered immune responses in the brain
themselves. Our understanding of cross-talk between the immune and nervous
systems is still in its infancy and a better
understanding of both the neuroprotec-
tive and destructive roles of the immune
response within the CNS is essential for
major advances in treating diseases with
an immune component. We also need
a much better understanding of both the
roles and balance of immune responses
in the healthy brain during neural develop-
ment and aging. Can we alter this balance
to better and more subtly control the
immune response and neural inflamma-
tion in typical development and aging, as
well as during disease? The development
of more specific therapeutic interventions
will require defining precise roles for
immune molecules and cells in the CNS
at specific ages, and the balance between
protective and destructive responses in
the CNS in specific disease contexts.
Given the rapid progress in this very young
field of neuroimmunology, it is possible
that we could even devise ways to protect
the functions of immune molecules on
neurons that mediate neuronal growth
and plasticity while allowing other impor-
tant, but less destructive aspects of the
CNS immune response to occur.
Finally, neural-immune crosstalk also
has profound implications for public
health policy. Growing evidence that
maternal immune activation could
increase the incidence of autism or
schizophrenia in offspring suggests that
healthcare providers should revisit the
pros and cons of using anti-inflammatory
drugs in pregnancy with the goal of devel-
oping drugs that prevent a proinflamma-
tory response in the CNS without
damaging the fetus. Another issue for
society right now is whether, and when,
pregnant mothers should be given the
seasonal flu and H1N1 vaccines. While
the flu can be extremely harmful to preg-
nant women, the effects of stimulating
the immune response with two flu
vaccines during pregnancy are unknown.
Absent the luxury ofwaiting for large-scale
study results, recommendations that
pregnant women receive both vaccines
are valid based on current knowledge of
the dangers of natural flu infection during
gestation. However, since the negative
effects of immune stimulationduring preg-
nancy are likely determined by suscepti-
bility factors, our understanding of factors
that cause aberrant baseline immuneNeuron 6responses in some pregnant women
must be improved and better methods for
susceptibility screening developed soon.
It is also important to note that neural-
immune crosstalk could be affected by
the current schedule of childhood immuni-
zations. Although there is some epidemio-
logical evidence that immunizations are
not likely to have a direct role in the
ontogeny of autism (Immunization Safety
Review Committee, 2004), it is still
possible that responses to the number
and combinations of vaccinations given
at some visits could contribute to cogni-
tive changes in children who may already
have altered immune responses. Natural
infections in an individual with a dysfunc-
tional immune system might have an
equally deleterious effect. Thus, a better
understanding of the effects of immune
activation during gestation and early post-
natal development, especially in the
context of increased disease suscepti-
bility, will be critical to either validate our
current health policies or modify them for
specific populations of individuals.
Although at this point the relationship
between the neural and immune systems
is still emerging, the long-lasting impact
of current studies may be profound. A
whole-systems approach is becoming
critical to the successful study and treat-
ment of both neurodevelopmental and
neurodegenerative disorders. We have
now come to realize that beyond its tradi-
tional role in host defense, the immune
system can be considered as a diffuse
sensory organ, which works in concert
with the nervous system to achieve and
maintain homeostasis throughout the
body. One could imagine that in the
future, evaluation of immune function
may be essential to understanding and
treating many neurological and psychi-
atric disorders. Breaking down the
boundaries between the fields of immu-
nology and neuroscience is not only
intellectually exciting, but the future of
our health may depend upon it!
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